Success
Alert
Please select a Day.
Info
- NSE
- BSE
Samco Stock Rating
1
Sector: Pharmaceuticals & Drugs
Add to
- Portfolio
- Watchlist
- Messages
- SMS Alert
Follow Following
Sector:Pharmaceuticals & Drugs
Add to
- Portfolio
- Watchlist
- Messages
- SMS Alert
Follow Following
105.40
-1.10 (-1.03%)
As on 22 Feb, 2024 | 03:58
Open Trading A/c
Day Range
102.90
108.00
L H
52 Week Range
45.00
129.00
L H
Volume
117,093
*
* BSE Market Depth (22 Feb 2024)
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 99 | 105.15 | 105.50 | 155 |
| 50 | 105.10 | 106.80 | 50 |
| 20 | 105.00 | 106.95 | 100 |
| 500 | 104.60 | 107.00 | 102 |
| 200 | 104.55 | 107.35 | 25 |
| 0 | Total | Total | 0 |
Bid / Ask
0.00 / 0.00
Advance Chart
105.50
-1.35 (-1.26%)
As on 22 Feb, 2024 | 04:01
Open Trading A/c
Day Range
103.50
107.00
L H
52 Week Range
45.01
128.79
L H
Volume
20,440
*
* BSE Market Depth (22 Feb 2024)
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 99 | 105.15 | 105.50 | 155 |
| 50 | 105.10 | 106.80 | 50 |
| 20 | 105.00 | 106.95 | 100 |
| 500 | 104.60 | 107.00 | 102 |
| 200 | 104.55 | 107.35 | 25 |
| 0 | Total | Total | 0 |
Bid / Ask
0.00 / 0.00
Advance Chart
NSE
- #KnowBeforeYouInvest
- Forecast
- Strengths (5) Rising Net Cash Flow and Cash from Operating activity
- Weaknesses (3) Decline in Net Profit with falling Profit Margin (QoQ)
- Opportunities (2) Highest Recovery from 52 Week Low
- Threats (0) No Threat for this stock
Note :Financial Information is based on consolidated numbers.
Note :Financial Information is based on consolidated numbers.
Note :Financial Information is based on consolidated numbers.
Note :Financial Information is based on consolidated numbers.
MC Essentials
38% Pass
This represents current trend.Click here for disclaimer.
Trend
Stock not eligible for rating
Financials
Ownerships
Industry Comparison
Others
Disclaimer
The Estimates data displayed by Moneycontrol is not a recommendation to buy or sell any securities. Estimates data is a third party aggregated data provided by S&P Global Market Intelligence LLC for informational purposes only. The Company advises the users to check with duly registered and qualified advisors before taking any investment decision. The Company does not guarantee the accuracy, adequacy or completeness of any information/data and is not responsible for any errors or omissions or for the results obtained from the use of such information/data. The Company or anyone involved with the Company will not accept any liability for loss or damage as a result of reliance on the Estimates data. The Company does not subscribe or endorse any of the services and/or content offered by such third party.
Hits/Misses
QUARTERLY (Rs.)
- EPS
- Net Profit
- Revenue
# of Beats
# of Misses
# of Inline
# of Beats
# of Misses
# of Inline
# of Beats
# of Misses
# of Inline
- Overview
- Chart
- Forecast
- MC Insights
- MC Technicals
- Scans
- News
- Forum
- Research
- Deals
- Insider
- Corp Action
- Financials
- Shareholding
-
Peers About
| Open | 108.00 |
| Previous Close | 106.50 |
| Volume | 117,093.00 |
| Value (Lacs) | 123.42 |
| VWAP | 104.88 |
| Beta | |
| Mkt Cap (Rs. Cr.) | 2,299 |
| High | 108.00 |
| Low | 102.90 |
| UC Limit | 111.80 |
| LC Limit | 101.20 |
| 52 Week High | 129.00 |
| 52 Week Low | 45.00 |
| Face Value | 1.00 |
| All Time High | 338.50 |
| All Time Low | 9.50 |
| 20D Avg Volume | 0 |
| 20D Avg Delivery(%) | -- |
| Book Value Per Share | 22.74 |
| Dividend Yield | 0.00 |
| TTM EPS See historical trend | -4.87 |
| TTM PE See historical trend | -- (Low PE) |
| P/B See historical trend | 4.64 (Average P/B) |
| Sector PE | 55.13 |
VWAP And Current Price Comparison
Standalone
Consolidated
Advanced Chart
Click here to expand
*Delayed by 20 seconds.
Forecast
Earnings Forecast
Actuals Estimates
- EPS
- Net Profit
- Revenue
Valuations
Consensus Recommendations
- Buy
- Outperform
- Hold
- Underperform
- Sell
Hits/Misses
QUARTERLY (Rs.)
- EPS
- Net Profit
- Revenue
# of Beats
# of Misses
# of Inline
# of Beats
# of Misses
# of Inline
# of Beats
# of Misses
# of Inline
MC Insights
Stock not eligible for rating
Get detailed analysis with Moneycontrol Stock Insights.
Get detailed analysis with Moneycontrol Stock Insights.
Price
- 18.29% away from 52 week high
Financials
Piotroski Score
indicates
Industry Comparison
- Market Cap - Above industry Median
Shareholding Pattern
- Promoters holding remains unchanged at 69.57% in Dec 2023 qtr
- Investor Presentation
- Earnings Transcripts
- FDA Warnings
- Credit Rating
- Resignation
Investor Presentation
Earnings Transcripts
FDA Warnings
Credit Rating
Resignation
MC Technicals
- Daily
- Weekly
- Monthly
TECHNICAL RATING
This represents current trend.
Click here for disclaimer.
Trend
See Detail
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
Pivot levels
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
Pivot levels
| R1 | - - | Pivot - - | S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
Moving Averages
| Days | |
|---|---|
| 5 | - - |
| 10 | - - |
| 20 | - - |
| 50 | - - |
| 100 | - - |
| 200 | - - |
TECHNICAL RATING
This represents current trend.
Click here for disclaimer.
Trend
See Detail
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
Pivot levels
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
Pivot levels
| R1 | - - | Pivot - - | S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
Moving Averages
| Days |
|---|
TECHNICAL RATING
Thisrepresents current trend.
Click here fordisclaimer.
Trend
See Detail
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
Pivot levels
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
Pivot levels
| R1 | - - | Pivot - - | S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
Moving Averages
| Days |
|---|
SCANS
Zero Debt
Debt Free Companies
FII Buying
Companies in which FIIs have increased holding QoQ
5X Premium to Book Value
Companies trading at more than 5 times their book values
Debt Free, Pledge Free
List of Companies with Zero Debt and Pledge
Price to Book Value Above Industry
Companies with Price to Book Value Above Industry
Triple Trouble
Companies reporting Falling Sales, NPM And Profits
Powered by: 
SCANS
Zero Debt
Debt Free Companies
FII Buying
Companies in which FIIs have increased holding QoQ
5X Premium to Book Value
Companies trading at more than 5 times their book values
Debt Free, Pledge Free
List of Companies with Zero Debt and Pledge
Price to Book Value Above Industry
Companies with Price to Book Value Above Industry
Triple Trouble
Companies reporting Falling Sales, NPM And Profits
Falling Quarterly Profits
Companies that have shown a fall in QoQ Profits as per their latest results
Price and Volume
Price Performance
| 1 Week | --% | |
| 1 Month | --% | |
| 3 Months | --% | |
| YTD | --% | |
| 1 Year | --% | |
| 3 Years | --% |
Historical Prices
Volume Analysis
News
Suven Life Sci Consolidated December 2023 Net Sales at Rs 2.45 crore, down 18.37% Y-o-Y
Feb 01 2024 12:13 PM
-
Suven Life Sci Standalone December 2023 Net Sales at Rs 2.45 crore, down 18.37% Y-o-Y Feb 01 2024 10:23 AM
-
Suven Life Sci Consolidated September 2023 Net Sales at Rs 3.06 crore, down 30.25% Y-o-Y Nov 06 2023 03:03 PM
-
Suven Life Sci Standalone September 2023 Net Sales at Rs 3.06 crore, down 30.25% Y-o-Y Nov 06 2023 10:48 AM
-
Suven Life Sci Consolidated June 2023 Net Sales at Rs 3.80 crore, up 7.29% Y-o-Y Aug 08 2023 06:47 PM
+ See More
Forum
Community Sentiments
Data not Available
What's your call on today?
Read 0 investor views
BUY SELL HOLD
-
radiant_sun
Suven Life Sci
Follow
1.11 PM Feb 14th
View more
Posted by : radiant_sun
- Like 0
- Reply
reply Cancel
- Share
- Repost
Repost this message
Did Suven get a patent??? All I can see in the website is "Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder... 
Repost Cancel
You will now receive notification when someone reply to this message.
-
SAIndian
Suven Life Sci
Follow
9.42 AM Feb 14th
good to see suven life science started getting stock analysts coverage. vaishali parkekh has recommended BUY with 118 target View more
Posted by : SAIndian
- Like 0
- Reply
reply Cancel
- Share
- Repost
Repost this message
good to see suven life science started getting stock analysts coverage. vaishali parkekh has recommended BUY with 118 target
Repost Cancel
You will now receive notification when someone reply to this message.
-
SAIndian
Suven Life Sci
Follow
10.10 AM Feb 13th
View more
Posted by : SAIndian
- Like 0
- Reply
reply Cancel
- Share
- Repost
Repost this message
more news on tv - US patent is officially received, Suven is koving to final stage of trail after which they can launch the medicine. great times ahead for suven life science with this patent, all other companies have to pay to Suven for mf... 
Repost Cancel
You will now receive notification when someone reply to this message.
+ See More
See More
Broker Research
28 May, 2019
Dolat Capital
| Reco Price 246.13 | Target Price 310 |
07 Feb, 2019
Dolat Capital
| Reco Price 210.23 | Target Price 315 |
03 Sep, 2018
Arihant capital markets
| Reco Price 250.83 | Target Price 325 |
17 May, 2018
Dolat Capital
| Reco Price 171.81 | Target Price 350 |
REFINITIV Report
- Company analysis giving insights of fundamentals, earnings, relative valuations, risk, price momentum and inside trading.
- Thomson Reuters proprietary rating of stock on scale of 1 to 10
- Industry ranking and detailed sector analysis of recent happening in sector
- Analyst rating like Buy/Sell/Hold with Earnings estimates with 1 year price target
or
Broker Research
Deals
- Block Deal
- Bulk Deal
No Data For Block Deals.
*Transaction of a minimum quantity of 500,000 shares or a minimum value of Rs 5 crore.
Block Deal
11 Jan, 2024
GRAVITON RESEARCH CAPITAL LLP
| Qty 1428543 | Price 121.82 | % Traded 0.66 |
11 Jan, 2024
GRAVITON RESEARCH CAPITAL LLP
| Qty 1428543 | Price 121.7 | % Traded 0.66 |
13 Sep, 2023
GRAVITON RESEARCH CAPITAL LLP
| Qty 1534944 | Price 78.12 | % Traded 0.70 |
13 Sep, 2023
GRAVITON RESEARCH CAPITAL LLP
| Qty 1534944 | Price 78.2 | % Traded 0.70 |
23 Apr, 2021
GRAVITON RESEARCH CAPITAL LLP
| Qty 640960 | Price 109.64 | % Traded 0.29 |
23 Apr, 2021
GRAVITON RESEARCH CAPITAL LLP
| Qty 640960 | Price 109.97 | % Traded 0.29 |
17 Dec, 2020
ALPHA LEON ENTERPRISES LLP
| Qty 656474 | Price 104.94 | % Traded 0.30 |
17 Dec, 2020
ALPHA LEON ENTERPRISES LLP
| Qty 627462 | Price 105.08 | % Traded 0.29 |
*A bulk deal is a trade where total quantity of shares bought or sold is more than 0.5% of the equity shares of a company listed on the exchange.
+ Show More
Bulk Deal
Insider Transaction Summary
- Insider
- SAST
29 Mar, 2022
Jasti Property and Equity Holdings Private Limited (in its capacity as sole trustee of the Jasti Family Trust)
Promoter Group
| Qty 18100000 | Price 81.57 | % Traded 14.22 | Post Tnx Hold. 64.98% |
06 Apr, 2021
Jasti Property and Equity Holdings Private Limited (in its capacity as sole trustee of the Jasti Family Trust)
Promoter Group
| Qty 18100000 | Price 81.57 | % Traded 14.22 | Post Tnx Hold. 4.98% |
02 Sep, 2020
VENKATA RAMUDU JASTHI
Directors Immediate Relative
| Qty 15000 | Price 49.3 | % Traded 0.01 | Post Tnx Hold. 0.05% |
31 Aug, 2020
VENKATA RAMUDU JASTHI
Directors Immediate Relative
| Qty 10000 | Price 53.81 | % Traded 0.01 | Post Tnx Hold. 0.04% |
27 Aug, 2020
VENKATA RAMUDU JASTHI
Directors Immediate Relative
| Qty 20000 | Price 52.72 | % Traded 0.02 | Post Tnx Hold. 0.03% |
24 Aug, 2020
VENKATA RAMUDU JASTHI
Directors Immediate Relative
| Qty 20000 | Price 50.01 | % Traded 0.02 | Post Tnx Hold. 0.02% |
*Disclosures under SEBI Prohibition of Insider Trading Regulations, 2015
18 Nov, 2022
Jasti Property & Equity Holdings Pvt Ltd & PACs Acquisition
Promoter
| Qty 57235701 | Price 0 | % Traded 4.59 | Post Tnx Hold. 69.57% |
29 Mar, 2022
Jasti Property & Equity Holdings Pvt Ltd & PACs Acquisition
Promoter
| Qty 18100000 | Price 0 | % Traded 4.98 | Post Tnx Hold. 64.98% |
06 Apr, 2021
Jasti Property and Equity Holdigns Pvt Ltd & PACs
Promoter
| Qty 0 | Price 0 | % Traded 0.00 | Post Tnx Hold. 60% |
30 Mar, 2016
Jasti Property and Equity Holdigns Pvt Ltd Acquisition
Promoter
| Qty 550000 | Price 0 | % Traded 0.43 | Post Tnx Hold. 60% |
02 Sep, 2015
Jasti Property & Equity Holdings Pvt Ltd Acquisition
Promoter
| Qty 162424 | Price 0 | % Traded 0.13 | Post Tnx Hold. 59.57% |
12 Mar, 2015
Jasti Property & Equity Holdings Pvt Ltd Acquisition
Promoter
| Qty 75652576 | Price 0 | % Traded 59.44 | Post Tnx Hold. 59.44% |
*Disclosures under SEBI SAST (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
Corporate Action
- Announcements
- Board Meetings
- Dividends
- Bonus
- Splits
- Rights
- AGM/EGM
06 Feb, 2024 | 12:36PM
Suven Life Sciences LimitedSuven Life Sciences Limited has informed the Exchange regarding a press release dated February 06, 2024, titled "Suven Life Sciences Announc....
06 Feb, 2024 | 11:15AM
Suven Life Sciences - Announcement under Regulation 30 (LODR)-Press Release / Media ReleasePlease find enclosed News Release of our company
05 Feb, 2024 | 05:22PM
Suven Life Sciences - Announcement under Regulation 30 (LODR)-Monitoring Agency ReportEnclosed herewith Monitoring Agency report for quarter ended December 31, 2023
+ See More
| Date | Agenda |
|---|
+ See More
| Ex-Date | Type | Dividend (Rs) |
|---|
+ See More
| Announcement Date | Ex-Bonus | Ratio |
|---|
+ See More
| Ex-Split | Old FV | New FV |
|---|
+ See More
| Ex-Right | Ratio | Premium |
|---|
+ See More
| Date | Agenda |
|---|
+ See More
Financials
- Consolidated
- Standalone
- Overview
- Income Statement
- Balance Sheet
- Cash Flow
- Ratios
(Rs. Cr)
- Revenue
- Net Profit
- EPS
- BVPS
- ROE
- Debt to Equity
- Quarterly
- Half Yearly
- Nine Months
- Annual
Detailed Financials
- Balance Sheet
- Quarterly Results
- Half Yearly Results
- Nine Months Results
- Yearly Results
- Cash Flows
- Ratios
- Capital Structure
- Overview
- Income Statement
- Balance Sheet
- Cash Flow
- Ratios
(Rs. Cr)
- Revenue
- Net Profit
- EPS
- BVPS
- ROE
- Debt to Equity
- Quarterly
- Half Yearly
- Nine Months
- Annual
Detailed Financials
- Balance Sheet
- Quarterly Results
- Half Yearly Results
- Nine Months Results
- Yearly Results
- Cash Flows
- Ratios
- Capital Structure
PEERS
| Company Name | Price | % Chg | MCap(Cr) | TTM PE | P/B | ROE(%) | 1 Yr Perform(%) | Net Profit(Rs.) | Net Sales(Rs.) | Debt to Equity |
|---|---|---|---|---|---|---|---|---|---|---|
| Suven Life Sci | 105.40 | -1.03 | 2,298.50 | - | 4.64 | -31.51 | 87.38 | -118 | 13 | 0.00 |
| Sun Pharma | 1,558.05 | 0.95 | 373,828.39 | 41.97 | 6.68 | 15.13 | 60.86 | 8,560 | 43,885 | 0.11 |
| Cipla | 1,453.30 | 0.41 | 117,334.41 | 31.68 | 5.01 | 11.96 | 50.98 | 2,835 | 22,753 | 0.02 |
| Dr Reddys Labs | 6,363.95 | 0.23 | 106,156.67 | 20.30 | 4.56 | 19.35 | 42.16 | 4,470 | 24,669 | 0.05 |
| Divis Labs | 3,645.40 | -0.10 | 96,773.92 | 69.97 | 7.58 | 14.28 | 24.82 | 1,823 | 7,767 | 0.00 |
+ See More
About the Company
Suven Life Sciences Ltd is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets.The different business units of the company includes C.R.A.M.S-The companys main thrust is in Contract Research and Manufacturing Services (C-R-A-M-S). Suven`s C-R-A-M-S serves as many as 22 global Life Science and Fine Chemical Companies by developing and supplying cost effective Pharmaceutical and Agro Chemical Intermediates for New Chemical Entities (NCE`s).DDDSS-Drug Discovery & Development Support Services (DDDSS) aims to provide Contract Drug Discovery & Development services in Medicinal chemistry, Process chemistry, Analytical chemistry, In-vitroScreening, DMPK, Brain Microdialysis, CV Safety, In-vivo Metabolic Disorders & CNS Pharmacology, Phase-I Bio-analysis and Discovery Toxicology.The product range of the company includes Advanced Intermediates,IntermediatesActive,Pharmaceutical Ingredients (APIs ) and Stock Chemicals for Disposal..The company also in the business segment of Services (DDDSS), Manufacturing (CRAMS).
-
Registered Office
- Address
8-2-334, SDE Serene Chambers,,6th Floor, Avenue 7,,Road No. 5, Banjara Hills,
- City
Hyderabad
- State
Telangana
- Pin Code
500034
- Tel. No.
40-23541142
- Fax No.
40-23541152
- Email
info@suven.com
- Internet
- Address
-
Registrars
- Address
Selenium Tower B, Plot No. 31-32,,Gachibowli, Financial District, Nanakramguda,Seri
- City
Hyderabad 500032
- State
Telangana
- Tel. No.
040-67161500, 67162222, 33211000
- Fax No.
040-23420814, 23001153
- Email
einward.ris@karvy.com
- Internet
- Address
-
Management
- Venkateswarlu Jasti
Chairman & CEO
- Sudharani Jasti
Whole Time Director
- J A S Padmaja
Director
- Seyed E Hasnain
Director
- M Gopalakrishna
Director
+ See More
- Venkateswarlu Jasti
-
Included In
- BSE 100
No
- BSE 200
No
- SENSEX
No
- CNX MIDCAP 200
No
- NIFTY 50
No
- BSE 500
No
- BSE 100
-
Details
- BSE:
530239
- NSE:
SUVEN
- Series
BE
- ISIN
INE495B01038
- BSE:
